Glofitamab and chidamide for relapsed or refractory DLBCL
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of two drugs, glofitamab and chidamide, for people with diffuse large B-cell lymphoma (DLBCL) that has come back or not responded after at least two prior treatments. The goal is to see if this combination can help when other options have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have DLBCL that came back or didn't respond to at least two prior treatments, including one with an anthracycline (a type of chemo) and one with an anti-CD20 drug (like rituximab).
- You must have at least one tumor that can be measured on scans, with lymph nodes larger than 1.5 cm or other lesions larger than 1 cm.
- You must be able to get around and take care of yourself (ECOG 0 or 1).
- Your liver, kidney, and blood counts must be within certain limits.
- You cannot have active infections, certain heart conditions, or a history of cancer in the brain or central nervous system.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called glofitamab for people with a type of lymphoma (DLBCL) that has come back or not responded to at least two prior treatments. The goal is to see if this drug can help shrink tumors or stop the disease from progressing.
This study looks at how well a drug called Glofitamab works in Chinese adults with a type of lymphoma (diffuse large B-cell lymphoma) that has come back or not gotten better after one round of standard treatment. It will help doctors understand more about its effects in real-world settings.
This trial tests a new drug called glofitamab combined with standard Pola-R-CHP chemotherapy for people with untreated DLBCL. The goal is to see if using PET scans and blood tests early on can guide treatment and improve outcomes.
This study looks at how well a new drug called glofitamab works in real life for people with a type of lymphoma that has come back or not improved after treatment. It aims to see if the drug is safe and effective outside of a clinical trial setting.
This trial tests a combination of radiation therapy, lenalidomide, and glofitamab for people with a type of lymphoma called DLBCL that has not responded to or has returned after initial treatment. The goal is to see if this combination can help when other treatments have failed.
This trial combines a targeted antibody treatment called glofitamab with radiation therapy for people whose diffuse large B-cell lymphoma has come back or not responded to previous treatments. It aims to see if this combination can help control the disease.
Hear when a new Diffuse Large B-Cell Lymphoma-Recurrent trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.